All News
Filter News
Found 100 articles
-
Cerevance to Present at the BIO CEO & Investor Conference
2/3/2020
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the company will present at the BIO CEO & Investor Conference, taking place in New York, Feb. 10 – 11, 2020.
-
Takeda Eyes 12 New Drug Approvals by 2024, Hemophilia Gene Therapy May Not be a Competitor
1/21/2020
Over the past year, the company strived to transform itself into becoming a frontrunner in multiple areas, including cell and gene therapies. -
Charles River will use its strengths to help develop potential drug candidates across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience and rare disease.
-
BioSpace Movers & Shakers, Jan. 10
1/10/2020
Pharma and biotech companies bolster their executive leadership teams and boards of directors with this week's appointments. -
Cerevance Appoints Clinical Development Veteran Dr. Aoife Brennan to Board of Directors
1/7/2020
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced the appointment of Aoife Brennan, M.B., B.Ch., to its board of directors effective January 1, 2020.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
Ebb Therapeutics Debuts First-of-its-Kind Wearable Technology at CES 2020 to Help Consumers Manage Sleeplessness
1/5/2020
Created by a luminary sleep researcher and doctor, the intelligent device features novel cooling technology to calm "a racing mind"
-
The two companies will pair up to advance Turnstone’s lead program, RIVAL-01, in multiple cancer studies and will also work together to identify additional novel product candidates based on Turnstone’s vaccinia virus platform for future independent development.
-
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
-
Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders
12/17/2019
Multi-year research alliance will apply Cerevance’s NETSseq technology to GI disorders
-
Cerevance Initiates Phase 2 Trial of CVN424 for Parkinson’s Disease
12/4/2019
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, announced today the initiation of a Phase 2 clinical trial of CVN424, an oral, first-in-class compound that selectively modulates a novel, non-dopaminergic target selectively expressed in an important class of neurons in the striatum.
-
Cerevance to Present at the 31st Annual Piper Jaffray Healthcare Conference
11/26/2019
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced that Brad Margus, chief executive officer, will present the company’s target discovery and clinical development work during the 31st Annual Piper Jaffray Healthcare Conference taking place December 3-5, 2019 in New York, NY.
-
Cerevance to Present at the 2019 BIO Investor Forum
10/15/2019
Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, today announced that Brad Margus, Chief Executive Officer, will present the company’s target discovery and clinical development work during the 2019 BIO Investor Forum taking place October 22nd-23rd, 2019 in San Francisco, CA.
-
Cerevance, a pharmaceutical company focusing on central nervous system diseases, has developed a new process for peering into the gene expression of specific brain cells.
-
BioSpace Movers & Shakers, Aug. 23
8/23/2019
Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments. -
Ebb Therapeutics Names Eduard Röösli New CEO
8/22/2019
Ebb Therapeutics, a med-tech start-up that develops innovative products designed to help the sleep-deprived millions, announces that its added Eduard Röösli as its new President & CEO, effective immediately.
-
BioSpace Movers and Shakers, June 7
6/7/2019
Pharma and biotech companies strengthen their executive and leadership teams with new appointments. -
Cerevance Appoints CNS Drug Developer James Summers, Ph.D. as Scientific Advisor
6/3/2019
Dr. Summers to help guide Cerevance’s Drug Discovery and Development Efforts
-
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
4/30/2019
Results Demonstrate Safety of CVN424 and Enable Initiation of Phase 2 Study in Patients
-
BioSpace Movers and Shakers: April 19
4/19/2019
Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.